Algert Global LLC Purchases 31,115 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Algert Global LLC boosted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 185.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 47,920 shares of the biopharmaceutical company's stock after acquiring an additional 31,115 shares during the quarter. Algert Global LLC's holdings in Catalyst Pharmaceuticals were worth $1,000,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in CPRX. Vanguard Group Inc. increased its position in shares of Catalyst Pharmaceuticals by 4.9% during the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock valued at $175,957,000 after purchasing an additional 390,116 shares during the last quarter. Pacer Advisors Inc. grew its position in Catalyst Pharmaceuticals by 5.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company's stock valued at $61,681,000 after acquiring an additional 151,495 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Catalyst Pharmaceuticals by 7.1% during the fourth quarter. Renaissance Technologies LLC now owns 2,706,116 shares of the biopharmaceutical company's stock worth $56,477,000 after acquiring an additional 180,100 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Catalyst Pharmaceuticals by 8.7% in the 4th quarter. Northern Trust Corp now owns 1,503,566 shares of the biopharmaceutical company's stock worth $31,379,000 after acquiring an additional 119,766 shares during the last quarter. Finally, Boston Partners boosted its stake in shares of Catalyst Pharmaceuticals by 1.3% in the 4th quarter. Boston Partners now owns 1,291,868 shares of the biopharmaceutical company's stock valued at $27,325,000 after purchasing an additional 16,601 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Price Performance

CPRX stock traded down $0.25 during trading on Wednesday, reaching $23.40. The company had a trading volume of 1,177,607 shares, compared to its average volume of 1,109,858. The business has a 50 day moving average of $23.10 and a 200 day moving average of $22.44. The company has a market cap of $2.85 billion, a P/E ratio of 19.83, a PEG ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.75 and a 52 week high of $26.16.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This trade represents a 25.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gary Ingenito sold 44,904 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. This trade represents a 39.47% decrease in their position. The disclosure for this sale can be found here. Insiders own 10.40% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Robert W. Baird raised their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, March 3rd. HC Wainwright reiterated a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Stephens reissued an "overweight" rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Catalyst Pharmaceuticals has an average rating of "Buy" and an average target price of $32.29.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.